Literature DB >> 29299635

Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function.

Xiaoyu He1, Qiaohong Lai1, Cai Chen1, Na Li1, Fei Sun1, Wenting Huang1, Shu Zhang1, Qilin Yu1, Ping Yang1, Fei Xiong1, Zhishui Chen1, Quan Gong2, Boxu Ren2, Jianping Weng3, Décio L Eizirik4, Zhiguang Zhou5, Cong-Yi Wang6.   

Abstract

AIMS/HYPOTHESIS: Post-translational attachment of a small ubiquitin-like modifier (SUMO) to the lysine (K) residue(s) of target proteins (SUMOylation) is an evolutionary conserved regulatory mechanism. This modification has previously been demonstrated to be implicated in the control of a remarkably versatile regulatory mechanism of cellular processes. However, the exact regulatory role and biological actions of the E2 SUMO-conjugating enzyme (UBC9)-mediated SUMOylation function in pancreatic beta cells has remained elusive.
METHODS: Inducible beta cell-specific Ubc9 (also known as Ube2i) knockout (KO; Ubc9Δbeta) and transgenic (Ubc9Tg) mice were employed to address the impact of SUMOylation on beta cell viability and functionality. Ubc9 deficiency or overexpression was induced at 8 weeks of age using tamoxifen. To study the mechanism involved, we closely examined the regulation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) through SUMOylation in beta cells.
RESULTS: Upon induction of Ubc9 deficiency, Ubc9Δbeta islets exhibited a 3.5-fold higher accumulation of reactive oxygen species (ROS) than Ubc9f/f control islets. Islets from Ubc9Δbeta mice also had decreased insulin content and loss of beta cell mass after tamoxifen treatment. Specifically, at day 45 after Ubc9 deletion only 40% of beta cell mass remained in Ubc9Δbeta mice, while 90% of beta cell mass was lost by day 75. Diabetes onset was noted in some Ubc9Δbeta mice 8 weeks after induction of Ubc9 deficiency and all mice developed diabetes by 10 weeks following tamoxifen treatment. In contrast, Ubc9Tg beta cells displayed an increased antioxidant ability but impaired insulin secretion. Unlike Ubc9Δbeta mice, which spontaneously developed diabetes, Ubc9Tg mice preserved normal non-fasting blood glucose levels without developing diabetes. It was noted that SUMOylation of NRF2 promoted its nuclear expression along with enhanced transcriptional activity, thereby preventing ROS accumulation in beta cells. CONCLUSIONS/
INTERPRETATION: SUMOylation function is required to protect against oxidative stress in beta cells; this mechanism is, at least in part, carried out by the regulation of NRF2 activity to enhance ROS detoxification. Homeostatic SUMOylation is also likely to be essential for maintaining beta cell functionality.

Entities:  

Keywords:  Diabetes; Insulin content; Insulin secretion; NRF2; Oxidative stress; Pancreatic beta cell; SUMOylation; UBC9

Mesh:

Substances:

Year:  2018        PMID: 29299635     DOI: 10.1007/s00125-017-4523-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  24 in total

1.  Chrysophanol protects human bronchial epithelial cells from cigarette smoke extract (CSE)-induced apoptosis.

Authors:  Guorao Wu; Ting Yuan; He Zhu; Huilan Zhang; Jiakun Su; Lei Guo; Qing Zhou; Fei Xiong; Qilin Yu; Ping Yang; Shu Zhang; Biwen Mo; Jianping Zhao; Jibao Cai; Cong-Yi Wang
Journal:  Int J Mol Epidemiol Genet       Date:  2020-12-15

Review 2.  Mechanisms controlling pancreatic islet cell function in insulin secretion.

Authors:  Jonathan E Campbell; Christopher B Newgard
Journal:  Nat Rev Mol Cell Biol       Date:  2021-01-04       Impact factor: 94.444

Review 3.  Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell.

Authors:  Anjaneyulu Kowluru; Noah F Gleason
Journal:  Biochem Pharmacol       Date:  2021-12-28       Impact factor: 5.858

Review 4.  Posttranslational modifications in diabetes: Mechanisms and functions.

Authors:  Bin Chen; Jianing Zhong; Ang Hu; Haohong Zou
Journal:  Rev Endocr Metab Disord       Date:  2022-06-13       Impact factor: 9.306

5.  A post-translational balancing act: the good and the bad of SUMOylation in pancreatic islets.

Authors:  Patrick E MacDonald
Journal:  Diabetologia       Date:  2018-01-12       Impact factor: 10.122

Review 6.  Modulating NRF2 in Disease: Timing Is Everything.

Authors:  Matthew Dodson; Montserrat Rojo de la Vega; Aram B Cholanians; Cody J Schmidlin; Eli Chapman; Donna D Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-26       Impact factor: 13.820

7.  Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.

Authors:  Longmin Chen; Jing Zhang; Yuan Zou; Faxi Wang; Jingyi Li; Fei Sun; Xi Luo; Meng Zhang; Yanchao Guo; Qilin Yu; Ping Yang; Qing Zhou; Zhishui Chen; Huilan Zhang; Quan Gong; Jiajun Zhao; Decio L Eizirik; Zhiguang Zhou; Fei Xiong; Shu Zhang; Cong-Yi Wang
Journal:  Cell Death Differ       Date:  2021-01-18       Impact factor: 15.828

8.  SUMO-Modification of Human Nrf2 at K110 and K533 Regulates Its Nucleocytoplasmic Localization, Stability and Transcriptional Activity.

Authors:  Treniqka S Walters; Deneshia J McIntosh; Shalonda M Ingram; Lakeisha Tillery; Evangeline D Motley; Ifeanyi J Arinze; Smita Misra
Journal:  Cell Physiol Biochem       Date:  2021-03-27

9.  SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling.

Authors:  Liu Mei; Meiyu Qv; Hangyang Bao; Qiangqiang He; Yana Xu; Qin Zhang; Wei Shi; Qianlei Ren; Ziyi Yan; Chengyun Xu; Chao Tang; Musaddique Hussain; Ling-Hui Zeng; Ximei Wu
Journal:  Oncogene       Date:  2021-07-15       Impact factor: 9.867

10.  The E3 SUMO ligase PIASγ is a novel interaction partner regulating the activity of diabetes associated hepatocyte nuclear factor-1α.

Authors:  Alba Kaci; Magdalena Keindl; Marie H Solheim; Pål R Njølstad; Lise Bjørkhaug; Ingvild Aukrust
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.